Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
40 hedge funds and large institutions have $63.1M invested in Cellular Biomedicine Group, Inc. in 2019 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 4 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
0% more funds holding
Funds holding: 40 → 40 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
3% less capital invested
Capital invested by funds: $64.8M → $63.1M (-$1.7M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $16K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HA
HHLR Advisors
Grand Cayman,
Cayman Islands
|
+$3.17M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
+$623K |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$475K |
| 4 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$418K |
| 5 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$395K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$1.32M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$531K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$135K |
| 4 |
Bank of New York Mellon
New York
|
-$80.3K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$80.2K |
CBMG Hedge Fund Activity: Q3 2019 in Review
40 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q3 2019, worth a combined $63.1M — down 2.6% from $64.8M a quarter earlier.
Fund positioning in CBMG was balanced in Q3 2019: 4 funds opened new positions, 4 closed out, 16 added to existing stakes and 9 trimmed.
The largest buyer was HHLR Advisors, opening a new position worth an estimated $3.17M. The largest seller was AWM Investment Company, exiting entirely with an estimated $1.32M sold.
- 40 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $63.1M of Cellular Biomedicine Group, Inc. stock for Q3 2019, down 2.6% quarter-over-quarter.
- 4 funds opened new Cellular Biomedicine Group, Inc. positions in Q3 2019 and 4 closed out, a net change of 0 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q3 2019 was HHLR Advisors, an estimated $3.17M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q3 2019 was AWM Investment Company, an estimated $1.32M sold.
Based on aggregated 13F filings for Q3 2019.